Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00021047 · ClinicalTrials.gov registry record · Phase 1
Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor
A Phase 1 study, sponsored by National Institutes of Health Clinical Center (CC).
- Completed
- Registry status
- Phase 1
- Development phase
NCT00021047: Completed Phase 1 study, sponsored by National Institutes of Health Clinical Center (CC).
NCT00021047 is a Phase 1 study that has completed, run by National Institutes of Health Clinical Center (CC). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00021047, a Phase 1 study, has completed, sponsored by National Institutes of Health Clinical Center (CC).
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combining epirubicin, carboplatin, and capecitabine in treating patients who have unresectable locally advanced, metastatic, or recurrent solid tumor.
Interventions
- DRUG carboplatin
- DRUG capecitabine
- DRUG epirubicin hydrochloride
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-07 |
| Est. Completion | 2004-06 |
| Phase | Phase 1 |
What the finished NCT00021047 record still lists
NCT00021047 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which carboplatin is the first listed.
NCT00021047 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00021047 about?
NCT00021047 is a clinical study titled "Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combining epirubicin, carboplatin, and capecitabine in treating pat...
What is the current status of trial NCT00021047?
This trial is currently completed. It is a Phase 1 study. The study started on 2001-07. Estimated completion is 2004-06.
What interventions are being tested in trial NCT00021047?
The interventions under investigation include: carboplatin (DRUG), capecitabine (DRUG), epirubicin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00021047?
This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia